H
Hans Morreau
Researcher at Leiden University Medical Center
Publications - 157
Citations - 8967
Hans Morreau is an academic researcher from Leiden University Medical Center. The author has contributed to research in topics: Colorectal cancer & Germline mutation. The author has an hindex of 47, co-authored 157 publications receiving 7939 citations.
Papers
More filters
Journal ArticleDOI
HRPT2, encoding parafibromin, is mutated in hyperparathyroidism–jaw tumor syndrome
John D. Carpten,Christiane M. Robbins,Andrea Villablanca,Lars Forsberg,Silvano Presciuttini,Joan E. Bailey-Wilson,William F. Simonds,E. Gillanders,A.M. Kennedy,Jindong Chen,Sunita K. Agarwal,Raman Sood,Mary Pat Jones,Tracy Moses,C. Haven,David Petillo,P.D. Leotlela,Brian Harding,David Cameron,Anna A.J. Pannett,Anders Höög,H. Heath,Laura James-Newton,Bruce G. Robinson,R.J. Zarbo,Branca M. Cavaco,Wassif S. Wassif,N.D. Perrier,I.B. Rosen,Ulf Kristoffersson,Peter D. Turnpenny,Lars-Ove Farnebo,G. M. Besser,Charles E. Jackson,Hans Morreau,J.M. Trent,Rajesh V. Thakker,Stephen J. Marx,Bin Tean Teh,Catharina Larsson,Maurine R. Hobbs +40 more
TL;DR: The findings suggest that HRPT2 is a tumor-suppressor gene, the inactivation of which is directly involved in predisposition to HPT–JT and in development of some sporadic parathyroid tumors.
Journal ArticleDOI
Familial endometrial cancer in female carriers of MSH6 germline mutations
Juul T. Wijnen,W. J. F. De Leeuw,Hans F. A. Vasen,H. van der Klift,Pål Møller,Astrid Stormorken,Hanne Meijers-Heijboer,Dick Lindhout,Fred H. Menko,S Vossen,G Moslein,Carli M. J. Tops,A Brocker-Vriends,Ying Wu,Robert M. W. Hofstra,Rolf H. Sijmons,Cees J. Cornelisse,Hans Morreau,Riccardo Fodde +18 more
TL;DR: Hereditary non-polyposis colorectal cancer was shown to be caused by germline mutations in the DNA mismatch repair genes MSH2, MLH1, PMS1,PMS2 and MSH6, and many HNPCC families do not fully comply with the clinical Amsterdam criteria, and the causative mutations are unknown.
Journal ArticleDOI
Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance.
Yvonne M.C. Hendriks,Anja Wagner,Hans Morreau,Fred H. Menko,Astrid Stormorken,Franz Quehenberger,Lodewijk A. Sandkuijl,Pål Møller,Maurizio Genuardi,Hans C. van Houwelingen,Carli M. J. Tops,Marjo van Puijenbroek,Paul Verkuijlen,Gemma G. Kenter,Anneke M. van Mil,Hanne Meijers-Heijboer,Gita B Tan,Martijn H. Breuning,Riccardo Fodde,Juul T. Wijnen,A H J T Bröcker-Vriends,Hans F. A. Vasen +21 more
TL;DR: The aim of this study was to determine the cumulative risk of developing cancer in a large series of MSH6 mutation carriers, and recommended starting colonoscopic surveillance in female MSH 6 mutation carriers from age 30 years.
Journal ArticleDOI
The carcinoma–stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage
Wilma E. Mesker,Jan M. C. Junggeburt,Karoly Szuhai,Pieter de Heer,Hans Morreau,Hans J. Tanke,Rob A. E. M. Tollenaar +6 more
TL;DR: The carcinoma-percentage in primary colon cancer is a factor to discriminate between patients with a poor and a better outcome of disease and can be a candidate marker to further stratify into more individual risk groups.
Journal ArticleDOI
Detection of colorectal polyps in humans using an intravenously administered fluorescent peptide targeted against c-Met
Jacobus Burggraaf,Ingrid M C Kamerling,Paul Gordon,Lenneke Schrier,Marieke L. de Kam,Andrea J Kales,Ragnar Bendiksen,Bard Indrevoll,Roger Bjerke,Siver Andreas Moestue,Siavash Yazdanfar,Alexandra M. J. Langers,Marit Swaerd-Nordmo,Geir Torheim,Madhuri V Warren,Hans Morreau,Philip W. Voorneveld,Tessa Buckle,Fijs W. B. van Leeuwen,Liv-Ingrid Odegardstuen,Grethe Tang Dalsgaard,Andrew Healey,James C. H. Hardwick +22 more
TL;DR: This first-in-human pilot study shows that molecular imaging using an intravenous fluorescent agent specific for c-Met is feasible and safe, and that it may enable the detection of polyps missed by other techniques.